Telix Pharmaceuticals has signed a strategic agreement to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, creating what the companies describe as a vertically integrated radiopharmaceutical powerhouse spanning isotope production, manufacturing, and drug development, Telix announced September 21, 2026.¹ ITM shareholders are also eligible for up to $700 million in additional contingent consideration tied to regulatory approvals and commercial sales milestones for ITM-11 (177Lu-edotreotide), ITM's lead therapeutic candidate.¹
Key facts
- Companies: Telix Pharmaceuticals; ITM Isotope Technologies Munich
- Deal terms: $1.65 billion upfront; up to $700 million contingent consideration
- Consideration structure: ~$1.25 billion in Telix shares (Nasdaq ADRs) plus assumed debt
- Combined ownership: Telix shareholders ~76.3%; ITM shareholders ~23.7%
- Key asset: ITM-11 (177Lu-edotreotide) for GEP-NETs
- Key trial: COMPETE (NCT03049189); phase 3, 309 patients, met primary endpoint
- ITM scale: $273 million 2025 revenue; 40% CAGR (2021-2025); distribution in 65+ countries
- Isotope portfolio: Lutetium-177, actinium-225, terbium-161; only global-scale commercial Lu-177 producer
- Regulatory milestones: Up to $250 million tied to FDA approvals across 3 ITM-11 indications
- Timeline: Expected to close by end of fiscal year 2026, pending shareholder approval
"This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures," said Christian Behrenbruch, PhD, JD, managing director and group CEO of Telix, in a company press release.¹ "By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector."
What does ITM bring to the combined company?
Founded in 2004, ITM is a major supplier of therapeutic radioisotopes. The company has production capabilities spanning lutetium-177, actinium-225, and terbium-161 and is the only producer of globally scaled commercial-grade lutetium-177.¹ The company operates a profitable isotope manufacturing and distribution network spanning more than 65 countries, generating $273 million in revenue in 2025 at a 40% compound annual growth rate since 2021.¹ The global nuclear medicine market is forecast to reach $41 billion by 2034.¹
What clinical data support ITM-11?
ITM's pipeline includes ITM-11 (177Lu-edotreotide), a somatostatin receptor-targeted therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that has completed the phase 3 COMPETE trial (NCT03049189).¹,² The trial randomized 309 patients with advanced, somatostatin receptor-positive GEP-NETs 2:1 to receive the therapy or everolimus, meeting its primary endpoint with a statistically significant improvement in progression-free survival and a significantly higher objective response rate.³ The most common treatment-related adverse events were diarrhea and nausea, each in 36% of patients, and asthenia in 33%.³ A second, fully enrolled phase 3 trial, COMPOSE, is evaluating ITM-11 in an expanded indication, with an interim analysis expected in the first half of 2027.¹
What are the terms of the deal?
Telix will acquire 100% of ITM's shares on a cash-free, debt-free basis. After adjustments, ITM shareholders are expected to receive approximately $1.25 billion in Telix shares, released as Nasdaq American Depositary Receipts after applicable escrow periods. The contingent consideration is tied to FDA approvals of ITM-11 across 3 indications and to ITM-11 net global sales in fiscal year 2030 exceeding $150 million.¹
Upon completion, Telix shareholders will own approximately 76.3% and ITM shareholders approximately 23.7% of the combined company. The deal has been approved by Telix's board and ITM shareholders holding more than 90% of ITM's shares, and is expected to close by the end of fiscal year 2026, subject to Telix shareholder approval.¹
What did ITM say about the deal?
"Joining two radiopharmaceutical pioneers creates a company with unmatched breadth and depth across the value chain, supported by deep expertise and talent," said Andrew Cavey, MD, CEO of ITM, in the release.¹ "Together, we believe Telix and ITM will be uniquely positioned to capitalize on rapidly growing global demand for radiopharmaceuticals to the benefit of both shareholders and patients."
What are the limitations?
The combined company's pro forma 2026 revenue estimate of $1.3 billion is based on management projections rather than audited results, and projected positive earnings before interest, taxes, depreciation, and amortization from 2027 onward is contingent on realizing targeted synergies. The transaction remains subject to shareholder approval and is not yet complete.
References
- Telix Pharmaceuticals. Telix and ITM join forces to create a radiopharmaceutical powerhouse. Press release. Published September 21, 2026. Accessed September 21, 2026. https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE). ClinicalTrials.gov; NCT03049189. Updated August 7, 2026. Accessed September 21, 2026. https://clinicaltrials.gov/study/NCT03049189
- Walter T, Jann H, Ansquer C, et al. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. Lancet. 2026;408(10551):234-247. doi:10.1016/S0140-6736(26)00604-5
